Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19

[1]  D. Vordermark.  Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups , 2020, Radiation Oncology.

[2]  S. Cilla,et al.  Evolution of clinical radiotherapy physics practice under COVID-19 constraints☆ , 2020, Radiotherapy and Oncology.

[3]  Melanie Reuter-Oppermann,et al.  Influence of the pandemic dissemination of COVID-19 on radiotherapy practice: A flash survey in Germany, Austria and Switzerland , 2020, PloS one.

[4]  R. Corvò,et al.  COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)☆ , 2020, Radiotherapy and Oncology.

[5]  G. Mattiucci,et al.  Practical indications for management of patients candidate to Interventional and Intraoperative Radiotherapy (Brachytherapy, IORT) during COVID-19 pandemic – A document endorsed by AIRO (Italian Association of Radiotherapy and Clinical Oncology) Interventional Radiotherapy Working Group☆ , 2020, Radiotherapy and Oncology.

[6]  Dylan H. Morris,et al.  Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 , 2020, The New England journal of medicine.

[7]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[8]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[9]  J. Logue,et al.  Ten year outcomes of moderately hypofractionated salvage post prostatectomy radiotherapy and external validation of a contemporary multivariable nomogram for biochemical failure. , 2020, International journal of radiation oncology, biology, physics.

[10]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[11]  A. Zietman,et al.  Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial , 2019, International Journal of Radiation Oncology*Biology*Physics.

[12]  G. Rodrigues,et al.  Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial , 2019, The Lancet. Oncology.

[13]  R. Fisher,et al.  A Phase III Multi-Centre Randomised Trial comparing adjuvant versus early salvage Radiotherapy following a Radical Prostatectomy: Results of the TROG 08.03 and ANZUP “RAVES” Trial , 2019, International Journal of Radiation Oncology*Biology*Physics.

[14]  L. Beckman,et al.  Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial , 2019, The Lancet.

[15]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  M. Parmar,et al.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.

[17]  W. J. Morris,et al.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.

[18]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[19]  F. Calvo,et al.  Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial. , 2016, International journal of radiation oncology, biology, physics.

[20]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.

[21]  H. Sandler,et al.  Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[24]  T. Tammela,et al.  Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. , 2004, The Journal of urology.

[25]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.